MONOCLONAL GAMMOPATHY
Clinical trials for MONOCLONAL GAMMOPATHY explained in plain language.
Never miss a new study
Get alerted when new MONOCLONAL GAMMOPATHY trials appear
Sign up with your email to follow new studies for MONOCLONAL GAMMOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a multiple myeloma drug shield the kidneys in MGRS?
Disease control OngoingThis phase 2 trial tests whether isatuximab, an antibody drug already approved for multiple myeloma, can improve kidney function in people with monoclonal gammopathy of renal significance (MGRS). MGRS is a condition where abnormal proteins damage the kidneys. Participants receive…
Matched conditions: MONOCLONAL GAMMOPATHY
Phase: PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a cancer drug stop myeloma before it starts?
Disease control OngoingThis phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…
Matched conditions: MONOCLONAL GAMMOPATHY
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC